Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Blank

Showing results (61-70 of 89) with videos related to

Pageof 9
Sort By:
Science Translational Medicine|September 19, 2014
Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell responsePia Kvistborg, Daisy Philips, Sander Kelderman, et al.
European Journal of Cancer (Oxford, England : 1990)|August 11, 2018
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trialMatteo S Carlino, Georgina V Long, Dirk Schadendorf, et al.
Lancet (London, England)|August 21, 2017
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)Jacob Schachter, Antoni Ribas, Georgina V Long, et al.
European Journal of Cancer (Oxford, England : 1990)|September 7, 2016
Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanomaDirk Schadendorf, Reinhard Dummer, Axel Hauschild, et al.
The American Journal of Dermatopathology|December 2, 2020
Letter Regarding Editorial by Samuel ZagarellaMark B Faries, Paolo A Ascierto, Christian Blank, et al.
European Journal of Cancer (Oxford, England : 1990)|September 30, 2017
Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanomaOmid Hamid, Igor Puzanov, Reinhard Dummer, et al.
BJU International|October 27, 2021
Cytoreductive nephrectomy and exposure to sunitinib - a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trialYasmin Abu-Ghanem, Johannes V van Thienen, Christian Blank, et al.
Nature Communications|December 16, 2014
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanomaJudith Müller, Oscar Krijgsman, Jennifer Tsoi, et al.
Cancer Immunology, Immunotherapy : CII|February 27, 2019
First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysisBastian Schilling, Alexander Martens, Marnix H Geukes Foppen, et al.
Journal for Immunotherapy of Cancer|January 31, 2024
Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case seriesCatriona Harvey, Kazi J Nahar, Janet McKeown, et al.
Pageof 9

Showing results (61-70 of 89) with videos related to

Sort By:
Pageof 9
Science Translational Medicine|September 19, 2014
Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell responsePia Kvistborg, Daisy Philips, Sander Kelderman, et al.
European Journal of Cancer (Oxford, England : 1990)|August 11, 2018
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trialMatteo S Carlino, Georgina V Long, Dirk Schadendorf, et al.
Lancet (London, England)|August 21, 2017
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)Jacob Schachter, Antoni Ribas, Georgina V Long, et al.
European Journal of Cancer (Oxford, England : 1990)|September 7, 2016
Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanomaDirk Schadendorf, Reinhard Dummer, Axel Hauschild, et al.
The American Journal of Dermatopathology|December 2, 2020
Letter Regarding Editorial by Samuel ZagarellaMark B Faries, Paolo A Ascierto, Christian Blank, et al.
European Journal of Cancer (Oxford, England : 1990)|September 30, 2017
Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanomaOmid Hamid, Igor Puzanov, Reinhard Dummer, et al.
BJU International|October 27, 2021
Cytoreductive nephrectomy and exposure to sunitinib - a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trialYasmin Abu-Ghanem, Johannes V van Thienen, Christian Blank, et al.
Nature Communications|December 16, 2014
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanomaJudith Müller, Oscar Krijgsman, Jennifer Tsoi, et al.
Cancer Immunology, Immunotherapy : CII|February 27, 2019
First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysisBastian Schilling, Alexander Martens, Marnix H Geukes Foppen, et al.
Journal for Immunotherapy of Cancer|January 31, 2024
Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case seriesCatriona Harvey, Kazi J Nahar, Janet McKeown, et al.
Pageof 9